本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
紡織綜合所自2019年起創舉辦「台灣紡織論文研究發表會(Taiwan Textile Research Conference；簡稱TTRC)」，期望透過論文發表會促成國內紡織學術研究論文交流平台，為擴大投稿領域，去年度(2022年)增加「不織布」及「智慧型紡織品」等二領域，今年度(2023年)邁入第五屆，再增加「時尚流行設計」及「經營管理與行銷」二領域，並擴大與台灣區不織布工業同業公會、台灣智慧型紡織品協會及中華民國紡織業拓展會共同推動積極強化紡織論文發表會新能量。此外，自2022年起國內大學加入共同辦理論文發表會，論文發表件數更大幅成長。 今年「第5屆台灣紡織研究論文發表會」訂於5月26日(星期五)假實踐大學臺北校區 (台北市中山區大直街70號)舉辦，論文擴大為八大領域，包括「紡織材料纖維與加工」、「紡織工程、產品開發與檢驗」、「不織布開發與應用」、「智慧型紡織品開發與應用」、「時尚流行設計、「經營管理與行銷」等，合計119篇，其中口頭發表92篇分8個場次舉辦以及壁報發表27篇。在會場中實踐大學服裝設計學系更以「Reificate」為主題，展示該系學生運用庫存布結合3D模擬技術，發表20件永續創作服飾，為國內紡織永續發展注入新活水。 本年度論文發表會將開放對外旁聽，期許透過產學研交流對話，持續發揚舉辦「台灣紡織研究論文發表會」創辦精神，尤其鼓勵年輕學者深化學術研究，並進一步拔擢獎勵優秀的新進人才，開創嶄新多元的紡織學術研究風貌。 新聞連絡人：紡織綜合所 李淑瑛小姐 手機：0933-483660
MANCHESTER, England, May 18, 2023 /PRNewswire/ -- SmartKem, Inc. (OTCQB: SMTK), a company seeking to reshape the world of electronics with its disruptive organic thin-film transistors (OTFTs) that have the potential to drive the next generation of displays, is a gold sponsor of this year's Business Conference at Display Week 2023 taking place in Los Angeles, USA. SmartKem Chairman and Chief Executive Officer, Ian Jenks, will be giving the keynote speech on Wednesday, May 24th at 9:40am PT. DATE: Wednesday, May 24th, 2023TIME: 9:40am PTLOCATION: Los Angeles Convention Center Ian Jenks will be giving an in-person keynote speech titled 'The Next Generation of MicroLED Displays' as part of the Business Conference segment of Display Week. SmartKem recently announced that, together with its development partner, it has created the first monolithic microLED display using its high performance organic thin-film transistor (OTFT) technology. The novel display was created by printing an OTFT backplane directly on top of Gallium Nitride LEDs. SmartKem believes that this unique process has the potential to lower the cost and accelerate the commercialization of microLED displays. Consumer electronics companies are actively developing microLED displays which promise higher brightness, lower power consumption and longer lifetime. MicroLEDs are particularly important for portable powered displays such as smartwatches and AR/VR displays which cannot accommodate large batteries. Existing methods of creating microLED displays use physical transfer of LEDs from the wafer upon which they are manufactured to a separate TFT display backplane, where they must be laser welded to the contact pad of the transistor to make an electrical connection. Because high resolution displays require the transfer of millions of tiny LEDs, this process carries a significant risk of placement error. Even if a 99.9% placement yield is achieved, a full HD colour display will have over 6,000 faulty sub-pixel LEDs that would need to be identified, removed, and re-attached. SmartKem's patented core chemistry enables its semiconductor inks to be processed at 80°C, a significantly lower temperature than other existing methods. These lower temperature inks can be printed directly on top of the microLEDs which would be damaged at the higher temperatures used by other existing methods. This eliminates the mass transfer and laser welding processes, and the placement error described above. Importantly, existing low-cost manufacturing tools currently used for LCD backplane manufacturing can be used for OTFT fabrication. Attend the Business Conference on Wednesday, May 24th, to hear more about SmartKem's unique TRUFLEX® materials and its ability to deliver the next generation of displays. For more information on the conference, visit: https://www.displayweek.org/ SmartKem's OTCQB information can be found on the OTC Markets website: www.otcmarkets.com/stock/SMTK/overview About SmartKem SmartKem is seeking to reshape the world of electronics with its disruptive organic thin-film transistors (OTFTs) that have the potential to drive the next generation of displays. SmartKem's patented TRUFLEX® semiconductor and dielectric inks, or liquid electronic polymers, are used to make a new type of transistor that could potentially revolutionize the display industry. SmartKem's inks enable low temperature printing processes that are compatible with existing manufacturing infrastructure to deliver low-cost displays that outperform existing models. The company's electronic polymer platform can be used in a number of display technologies including microLED, miniLED and AMOLED displays for next generation televisions, laptops, augmented reality (AR) and virtual reality (VR) headsets, smartwatches and smartphones. SmartKem develops its materials at its research and development facility in Manchester, UK, its semiconductor manufacturing processes at the Centre for Process Innovation (CPI) at Sedgefield, UK and retains a field application office in Taiwan. The company has an extensive IP portfolio including 125 granted patents across 19 patent families and 40 codified trade secrets. For more information, visit: www.smartkem.com and follow us on LinkedIn and Twitter @SmartKemTRUFLEX. Forward-Looking Statements All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the SmartKem's expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors. These statements are not historical facts but rather are based on SmartKem Inc.'s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as "may," will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or elated expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
SHANGHAI, May 18, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced a strategic collaboration with UroViu Corporation ("UroViu"). Asieris Pharmaceuticals will obtain exclusive global rights to UroViu's patented technology of portable single-use cystoscope in the field of fluorescent imaging. Under the agreement, Asieris Pharmaceuticals will use this patented technology in combination with specific optical imaging agents to conduct research on the application of non-white light imaging technology in the diagnosis and postoperative monitoring of None-Muscle Invasive Bladder Cancer (NMBC). At the same time, Asieris Pharmaceuticals will be responsible for the global commercialization of the sterile single-use fluorescent Cystoscope. Previously, Asieris Pharmaceuticals entered a cooperation agreement with UroViu in 2021 for the exclusive registration and commercialization rights of its portable single-use flexible white light cystoscopy system in mainland China, Taiwan, Hong Kong and Macau. "There is still a huge unmet need for more accessible and safer fluorescent cystoscopy in the diagnosis and surveillance of bladder cancer."Dr. Susan Wang, Senior Vice President of Global Business Development & Strategic Partnership of Asieris said, "We are thrilled to deepen and expand our collaboration with UroViu which enabling us not only to broaden our technology portfolio, but also to expedite the implementation of Asieris' integrated strategy for bladder cancer diagnosis and treatment, aiming to provide more effective disease management options for bladder cancer patients." "We are excited about the possibilities that our expanded Partnership with Asieris will create. Our unique and expanding portfolio of single use endoscopic products are fulfilling UroViu's promise to greatly improve both the patient and provider experience, elevate the standard of care in a field with rapidly advancing technologies," said Bruce OuYang, Founder and CEO of UroViu. About UroViu Corporation UroViu has developed a proprietary, portable single-use endoscopic platform of minimally invasive devices to address the issues of device cross contaminations, patient discomfort and workflow inefficiencies.From this platform UroViu already have four (4) FDA cleared products launched and adopted by offices and clinics of urology, gynecology and urogynecology in USA. UroViu holds key patents for portable single-use endoscope and is expanding IP portfolio to include scope-drug, scope-device and robotic assisted surgery applications. UroViu is also actively partnering with drug and device companies for comprehensive disease management. UroViu is led by pioneers in the field of portable single-use endoscope innovation and manufacturing, and operated by an experienced medical device management team in Asia and USA. About Asieris Asieris Pharmaceuticals (688176.SH), founded in March 2010, is a global biopharma company specializing in the discovery, development and commercialization of innovative drugs that treat genitourinary tumors and other related diseases. We strive to improve human health and help people live a more dignified life. We aim to become a global pharma leader that integrates R&D, manufacturing, and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide. The company has been developing its proprietary R&D platform and core technologies, exploring new mechanisms of action, and efficiently screening and evaluating drug candidates. With a well-established in-house R&D system and expertise in global drug development, Asieris is committed to launching first-in-class drugs and other innovative products to address huge unmet needs in its areas of focus. Asieris is also enhancing its pipeline for genitourinary diseases via proprietary R&D and strategic partnerships, while closely following cutting-edge technologies and therapeutics. The company strives to discover and identify unmet medical needs, and adopts a forward-looking approach in product planning and life-cycle management. We aim to establish an outstanding portfolio that covers diagnosis and treatment in a bid to benefit more patients in China and globally. Contact: ymji@asieris.cn
ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibody to advance to the clinic in oncology and Antengene's third drug candidate to enter clinical studies in the U.S. The Phase I "PERFORM" study will evaluate the safety and tolerability, pharmacology, immunogenicity, and preliminary efficacy of ATG-031 in patients with advanced solid tumors or B-cell non-Hodgkin's lymphoma (B-NHL) SHANGHAI and HONG KONG, May 18, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that the Investigational New Drug (IND) for a Phase I study of the first-in-class anti-CD24 monoclonal antibody ATG-031 has received clearance from the U.S. Food and Drug Administration (FDA). The PERFORM trial is a first-in-human, multi-center, open-label, Phase I dose-finding study of ATG-031 in patients with advanced solid tumors or B-NHL. The primary objective of the study is to evaluate the safety and tolerability of ATG-031 as a monotherapy, and to determine the appropriate dose for Phase II studies. The secondary objective is to characterize the pharmacology, evaluate the immunogenicity, and assess the preliminary efficacy of ATG-031. ATG-031 is a first-in-class humanized anti-CD24 monoclonal antibody which inhibits the "don't eat me" signal in the tumor microenvironment (TME). ATG-031 was designed to specifically bind with the CD24 expressed on cancer cells with high affinity and block the interaction between CD24 and the Siglec-10 receptor expressed on the surface of tumor associated macrophages (TAMs), to enhance the macrophage-mediated phagocytosis of cancer cells and promote cytotoxic T-cell function in the tumor microenvironment. "Targeting the so-called 'don't eat me' signal is a promising therapeutic strategy for cancer treatment. In comparison to existing 'don't eat me' blockers such as anti-CD47 monoclonal antibodies, ATG-031 demonstrated a wider therapeutic window and the ability to overcome the on-target-off-tumor toxicities observed with CD47 inhibitors," said Dr. Bing Hou, Antengene's Executive Director of Drug Discovery and a co-inventor of ATG-031. "CD24 is a small and highly glycosylated protein that makes the development of antibodies particularly challenging. Through our persistent experimental efforts and by adopting unique discovery and screening strategies as well as leveraging our deep expertise on the target's biology, Antengene's discovery scientists successfully advanced ATG-031, an antibody with optimal characteristics, into clinical development in just three years. We are thrilled to see our in-house developed first-in-class drug entering the clinic and taking a major step towards benefiting patients." "We believe that therapies that can effectively mobilize the macrophage activity in the tumor microenvironment will be a very important element of cancer care," said Dr. Bo Shan, Antengene's Chief Scientific Officer. "The potential role of ATG-031 is supported by robust preclinical data that showed potent single agent in vivo efficacy and synergistic effects with chemotherapy or checkpoint inhibitors (CPIs). Therefore, we are very optimistic about the clinical development of ATG-031 and look forward to initiating the patient enrolment as early as possible." "In this clinical program for ATG-031, we will deploy an in-house developed companion diagnostic (CDx) antibody, thus adding a precision-medicine element to the program," said Dr. Amily Zhang, Antengene's Chief Medical Officer. "In addition to serving as a patient selection tool, the CDx antibody will help us to better understand the CD24 expression in normal and cancerous tissue. We are excited to learn more about the safety, tolerability and efficacy of ATG-031 through the clinical program and look forward to sharing the first data from this study in 2024." "ATG-031 is the world's first anti-CD24 antibody to be advanced to the clinic in oncology and Antengene's third drug candidate cleared to enter clinical studies in the U.S.," said Dr. Jay Mei, Antengene's Founder, Chairman and CEO. "I am very proud of the entire R&D organization, for innovating and advancing this proprietary asset, from bench to patient, in such a robust and efficient manner. We believe that targeting CD24 could represent a major oncological advancement and anticipate more exciting progress with this clinical program." About ATG-031 ATG-031 is a first-in-class humanized CD24 monoclonal antibody which inhibits the "don't eat me" signal and enhances macrophage-mediated phagocytosis of cancer cells. Tumor cells evade the surveillance of the human immune system by over-expressing "don't eat me" surface proteins that signal macrophages to prevent the detection and phagocytosis of cancer cells. CD24 (cluster of differentiation 24) is a prominent "don't eat me" signal that plays a significant role in tumor immune evasion by suppressing macrophage-mediated phagocytosis. Compared to CD47, another well-known "don't eat me" target, CD24 has more restricted distribution in normal tissue and higher expression in cancerous tissue. In addition, unlike CD47, CD24 is not expressed on human red blood cells, allowing for a wider therapeutic window and minimal on-target-off-tumor toxicity as a CD24-targeted therapy. As a novel innate immune checkpoint, CD24 orchestrates immune evasion through its interaction with the inhibitory receptor called Siglec-10 (sialic-acid-binding Ig-like lectin 10) expressed on tumor-associated macrophages (TAMs). Preclinical data presented in 2023 at the American Association for Cancer Research Annual Meeting (AACR 2023) demonstrated that ATG-031 can specifically bind to CD24 with nM affinity and block the interaction of CD24 and Siglec-10. Furthermore, ATG-31 induces efficient phagocytosis with a picomolar EC50 and stimulate the pro-inflammatory cytokines production by macrophages. About Antengene Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 28 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 9 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland China, Taiwan China, South Korea, Singapore and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the other risks and uncertainties described in the Company's Annual Report for year-end December 31, 2022, and subsequent filings with the Hong Kong Stock Exchange. For more information, please contact: Investor Contacts: Donald LungE-mail: Donald.Lung@antengene.com Mobile: +86 18420672158 PR Contacts:Peter QianE-mail: Peter.Qian@antengene.comMobile: +86 13062747000
- ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibody to advance to the clinic in oncology and Antengene's third drug candidate to enter clinical studies in the U.S. - The Phase I "PERFORM" study will evaluate the safety and tolerability, pharmacology, immunogenicity, and preliminary efficacy of ATG-031 in patients with advanced solid tumors or B-cell non-Hodgkin's lymphoma (B-NHL) HONG KONG, May 18, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that the Investigational New Drug (IND) for a Phase I study of the first-in-class anti-CD24 monoclonal antibody ATG-031 has received clearance from the U.S. Food and Drug Administration (FDA). The PERFORM trial is a first-in-human, multi-center, open-label, Phase I dose-finding study of ATG-031 in patients with advanced solid tumors or B-NHL. The primary objective of the study is to evaluate the safety and tolerability of ATG-031 as a monotherapy, and to determine the appropriate dose for Phase II studies. The secondary objective is to characterize the pharmacology, evaluate the immunogenicity, and assess the preliminary efficacy of ATG-031. ATG-031 is a first-in-class humanized anti-CD24 monoclonal antibody which inhibits the "don't eat me" signal in the tumor microenvironment (TME). ATG-031 was designed to specifically bind with the CD24 expressed on cancer cells with high affinity and block the interaction between CD24 and the Siglec-10 receptor expressed on the surface of tumor associated macrophages (TAMs), to enhance the macrophage-mediated phagocytosis of cancer cells and promote cytotoxic T-cell function in the tumor microenvironment. "Targeting the so-called 'don't eat me' signal is a promising therapeutic strategy for cancer treatment. In comparison to existing 'don't eat me' blockers such as anti-CD47 monoclonal antibodies, ATG-031 demonstrated a wider therapeutic window and the ability to overcome the on-target-off-tumor toxicities observed with CD47 inhibitors," said Dr. Bing Hou, Antengene's Executive Director of Drug Discovery and a co-inventor of ATG-031. "CD24 is a small and highly glycosylated protein that makes the development of antibodies particularly challenging. Through our persistent experimental efforts and by adopting unique discovery and screening strategies as well as leveraging our deep expertise on the target's biology, Antengene's discovery scientists successfully advanced ATG-031, an antibody with optimal characteristics, into clinical development in just three years. We are thrilled to see our in-house developed first-in-class drug entering the clinic and taking a major step towards benefiting patients." "We believe that therapies that can effectively mobilize the macrophage activity in the tumor microenvironment will be a very important element of cancer care," said Dr. Bo Shan, Antengene's Chief Scientific Officer. "The potential role of ATG-031 is supported by robust preclinical data that showed potent single agent in vivo efficacy and synergistic effects with chemotherapy or checkpoint inhibitors (CPIs). Therefore, we are very optimistic about the clinical development of ATG-031 and look forward to initiating the patient enrolment as early as possible." "In this clinical program for ATG-031, we will deploy an in-house developed companion diagnostic (CDx) antibody, thus adding a precision-medicine element to the program," said Dr. Amily Zhang, Antengene's Chief Medical Officer. "In addition to serving as a patient selection tool, the CDx antibody will help us to better understand the CD24 expression in normal and cancerous tissue. We are excited to learn more about the safety, tolerability and efficacy of ATG-031 through the clinical program and look forward to sharing the first data from this study in 2024." "ATG-031 is the world's first anti-CD24 antibody to be advanced to the clinic in oncology and Antengene's third drug candidate cleared to enter clinical studies in the U.S.," said Dr. Jay Mei, Antengene's Founder, Chairman and CEO. "I am very proud of the entire R&D organization, for innovating and advancing this proprietary asset, from bench to patient, in such a robust and efficient manner. We believe that targeting CD24 could represent a major oncological advancement and anticipate more exciting progress with this clinical program." About ATG-031 ATG-031 is a first-in-class humanized CD24 monoclonal antibody which inhibits the "don't eat me" signal and enhances macrophage-mediated phagocytosis of cancer cells. Tumor cells evade the surveillance of the human immune system by over-expressing "don't eat me" surface proteins that signal macrophages to prevent the detection and phagocytosis of cancer cells. CD24 (cluster of differentiation 24) is a prominent "don't eat me" signal that plays a significant role in tumor immune evasion by suppressing macrophage-mediated phagocytosis. Compared to CD47, another well-known "don't eat me" target, CD24 has more restricted distribution in normal tissue and higher expression in cancerous tissue. In addition，unlike CD47，CD24 is not expressed on human red blood cells，allowing for a wider therapeutic window and minimal on-target-off-tumor toxicity as a CD24-targeted therapy. As a novel innate immune checkpoint, CD24 orchestrates immune evasion through its interaction with the inhibitory receptor called Siglec-10 (sialic-acid-binding Ig-like lectin 10) expressed on tumor-associated macrophages (TAMs). Preclinical data presented in 2023 at the American Association for Cancer Research Annual Meeting (AACR 2023) demonstrated that ATG-031 can specifically bind to CD24 with nM affinity and block the interaction of CD24 and Siglec-10. Furthermore, ATG-31 induces efficient phagocytosis with a picomolar EC50 and stimulate the pro-inflammatory cytokines production by macrophages. About Antengene Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 28 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland China, Taiwan China, South Korea, Singapore and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the other risks and uncertainties described in the Company's Annual Report for year-end December 31, 2022, and subsequent filings with the Hong Kong Stock Exchange.
Manufacturing center expansion aims to become regional hub to serve North America and Southeast Asia markets and create 5,000 job opportunities in the Philippines MANILA, Philippines, May 17, 2023 /PRNewswire/ -- Sercomm Philippines, an affiliate of Sercomm Corporation, marked the grand opening of its new and advanced factory center, located in Carmelray Industrial Park 1 in Calamba, Philippines. Department of Trade and Industry (DTI) and Philippine Economic Zone Authority (PEZA) government officials and academic leaders were on hand for Factory Phase I opening ceremony. Sercomm Philippines Grand Opening Sercomm Philippines is a world-class professional networking equipment manufacturing site aiming to become Sercomm's regional hub to serve North America and Southeast Asia markets, providing a one-stop integrated service of R&D design, manufacturing and quality assurance. With a more than 2.5 billion peso investment, the manufacturing center is expected to attract local talent and create job opportunities, with an expected total employment of 5,000 employees. The 20,000 m2 facility, which specializes in wireless telecommunication devices such as 5G and fiber products, is a state-of-the-art, eco-friendly building adhering to the highest energy conservation standards. To cope with growing business, Sercomm also plans to construct Factory Phase II. Once completed, the manufacturing and R&D center will be 48,000 m2, and the total capacity will be further expanded to 40 million units in 2025. Sercomm, the parent company of Sercomm Philippines, is a leading global manufacturer of telecoms and broadband equipment. Headquartered in Taipei, Taiwan, Sercomm's global operations network covers markets in North and Central America, Europe, and the Asia Pacific. Its customer base includes the world's top service providers, networking OEMs, and system integrators. Sercomm was also recently recognized as "Asia's overall Best Managed Company" and "Asia's Best Company in Telecommunications" by FinanceAsia Magazine in 2022. Department of Trade and Industry (DTI) Secretary Fred Pascual said, "The Philippines has abundant natural resources and a vibrant and tech-savvy talent pool. Among the leading companies in the industry that have chosen to establish manufacturing facilities in the Philippines is Sercomm that is pioneering innovation. We at DTI welcome, with optimism, Sercomm's establishment of cutting-edge facilities in the Philippines, strengthening the country's industrial competitiveness and facilitating employment generation." "The Philippines' sufficient talent and geographical location between Eurasia and the Pacific Ocean makes it a suitable design and manufacturing center for North America and Southeast Asia. With the strong support of DTI in its inception, Sercomm chose Philippines to be its strategic regional operation center," James Wang, Sercomm Group Chairman stated, "The new Sercomm Philippines facility is an eco-friendly green building, where technology is integrated into humanities, and it also reflects the corporate commitment of sustainability." The company has also inked a LOI (Letter of Intent) with the Philippine Economic Zone Authority (PEZA). Sercomm Philippines reaffirmed its commitment to invest in the talent incubation and to expand its manufacturing facility and production scale in the economic zone, and PEZA will continuously provide any needed support. With Sercomm's strong collaboration in bringing the most advanced technologies to ecozones, high-tech industries will diversify PEZA's investment profile and increasingly raise the value chain. About Sercomm Corporation Sercomm Corporation (TWSE: 5388) is a worldwide leading manufacturer of telecom and broadband equipment. Founded in 1992, Sercomm has focused on developing embedded solutions to make networking simple and affordable. With its fully integrated engineering capability and its state-of-the-art manufacturing facility, Sercomm offers comprehensive telecom broadband solutions such as small cells, residential/enterprise gateways, and IoT products, and is now a global leader in the industry. Headquartered in Taipei, Taiwan, Sercomm's global operation network covers markets in North America, Europe, and the Asia Pacific region. Its customer base includes the world's top service provider, networking OEM, and system integrators. For more information, please visit www.sercomm.com.
A12 藝術空間
i-Taiwan
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
